MDT

86.39

-0.47%↓

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

MDT

86.39

-0.47%↓

113.4

-1.1%↓

VEEV

171.1

-1.1%↓

HQY

81.04

-3.14%↓

PHR.US

9.17

+3.97%↑

Начало・Списък с акции・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Отворен

СекторЗдравеопазване

1.39 -0.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.3599999999999999

Максимум

1.44

Ключови измерители
By Trading Economics
Приходи	-2.4M -40M
Продажби	6.2M 45M
Марж на печалбата	-90.427
Служители	485
EBITDA	-6M -38M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+77.61% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-175M 381M
Предишно отваряне	2.1
Предишно затваряне	1.39

Настроения в новините

By Acuity

14%

86%

29 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

1.13 / N/A Подкрепа & съпротива

Pacific Biosciences of California Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.04.2026 г., 23:17 ч. UTC

Печалби

Samsung Forecasts Record First-Quarter Operating Profit

6.04.2026 г., 23:00 ч. UTC

Горещи акции

Stocks to Watch: Health Insurers, Mawson, Owlet

6.04.2026 г., 22:13 ч. UTC

Значими двигатели на пазара

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6.04.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6.04.2026 г., 17:09 ч. UTC

Значими двигатели на пазара

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6.04.2026 г., 16:56 ч. UTC

Значими събития в новините

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6.04.2026 г., 14:47 ч. UTC

Значими двигатели на пазара

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6.04.2026 г., 23:58 ч. UTC

Пазарно говорене

Значими събития в новините

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6.04.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6.04.2026 г., 23:15 ч. UTC

Пазарно говорене

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

6.04.2026 г., 22:52 ч. UTC

Пазарно говорене

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6.04.2026 г., 22:14 ч. UTC

Пазарно говорене

Correction to Live Cattle Futures Article

6.04.2026 г., 20:56 ч. UTC

Пазарно говорене

Mexican Private Consumption Fell in January -- Market Talk

6.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

6.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.04.2026 г., 19:58 ч. UTC

Пазарно говорене

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6.04.2026 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6.04.2026 г., 19:06 ч. UTC

Пазарно говорене

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

6.04.2026 г., 19:03 ч. UTC

Пазарно говорене

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6.04.2026 г., 18:36 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 17:59 ч. UTC

Пазарно говорене

Значими събития в новините

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6.04.2026 г., 17:13 ч. UTC

Придобивния, сливания и поглъщания

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6.04.2026 г., 16:33 ч. UTC

Пазарно говорене

Oil Futures Steady as Market Awaits Trump -- Market Talk

6.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.04.2026 г., 14:59 ч. UTC

Печалби

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Pacific Biosciences of California Inc Прогноза

Ценова цел

By TipRanks

77.61% нагоре

12-месечна прогноза

Среден 2.38 USD 77.61%

Висок 3 USD

Нисък 1.5 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pacific Biosciences of California Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pacific Biosciences of California Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.13 / N/AПодкрепа & съпротива

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

29 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.